Newsletter | March 6, 2026

03.06.26 -- How Strategic Collaborations Can Accelerate Innovation And Create Value

FEATURED ARTICLE

How Strategic Collaborations Can Accelerate Innovation And Create Value

Platform biotechs should aim for partnerships that compound value over time, beyond a simple funding mechanism, writes Unnatural Products CEO Cameron Pye, Ph.D.  

INDUSTRY INSIGHTS

Optimizing Biologic Analytics With ICH Q2(R2) And Q14

Learn how to apply ICH Q2(R2) and Q14 to analytical procedures using QbD principles, ATP definition, and lifecycle management strategies to ensure regulatory alignment and product quality.

Revolutionizing Clinical Analytics

In this 4-part series, learn about AI-driven methods that streamline data mapping and highlight critical issues that allow clinical teams to focus on what truly matters.

Lyophilization: Protecting And Preserving Biologics

Discover how lyophilization revolutionizes biologic drug manufacturing and ensures potent, stable treatments for complex diseases.

Streamlining Clinical Trial Start-Up In Australia

Gain a comprehensive overview of how sponsors can accelerate clinical trial start-up in Australia, leveraging the nation’s unique strengths as a global hub for clinical research.

The Strategic Role Of Biostatistics In Clinical Trials

Early biostatistical input strengthens trial design, reduces risk, and ensures meaningful outcomes while strategic involvement drives smarter decisions. Learn why timing and collaboration matter.

CONTRIBUTE TO LIFE SCIENCE LEADER

Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.